IR
Cellid Co.,Ltd. leads research of anti-cancer immunotherapies and Vaccines for preventing infectious diseases
Disclosure
Total of 10posts
| Number | Title | Person with Duty to Submit | Receipt Date |
|---|---|---|---|
| 10 | [Revised]Outcomes of Annual Meeting of Shareholders | 2025-03-26 | |
| 9 | Outcomes of Annual Meeting of Shareholders | 2025-03-26 | |
| 8 | Submission of Audit Report | 2025-03-18 | |
| 7 | Decision on Paid-in Capital Increase | 2025-03-18 | |
| 6 | 30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations) | 2025-03-07 | |
| 5 | Resolutions for Convocation of General Meeting of Shareholders | 2025-02-26 | |
| 4 | Other Management Information(Voluntary Disclosure)(전자투표제 도입 결정) | 2025-02-26 | |
| 3 | Material Management Information related to Judgment of Investment(IND Approval Determination)(항암면역치료백신 BVACE6E7의 제1/2a상 임상시험 계획승인) | 2024-11-19 | |
| 2 | Material Management Information related to Judgment of Investment(Study Results)(COVID19 예방 백신 AdCLDCoV191 OMI의 제1/2상 임상시험 결과) | 2024-11-06 | |
| 1 | Release from designation as Investment Alert Issue & Prior notice on Re-designation | 2024-09-20 |
